Login
Navigate Fool.com
Will AMGN beat
the market?

Amgen, Inc.

NASDAQ: AMGN

Community Rating: 4 Stars: Favorite

115.46 -0.08 (-0.07%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $115.61
Previous Close $115.54
Daily Range $115.02 - $117.19
52-Week Range $94.15 - $128.96
Market Cap $87.2B
P/E Ratio 17.39
Dividend (Yield) $2.44 (2.1%)
Ex-Dividend Date
Dividend Pay Date
05/13/14
06/06/14
Volume 3,237,732
Average Daily Volume 4,014,187
Current FY EPS $8.10

How do you think AMGN
will perform against the market?

Top AMGN Bull/Bear Pitches

 

FreeMortal (< 20)
Submitted December 23, 2009

Steadily growing earnings. Excellent margins and ROE. PE is fair, but it looks like this will drop; not because the price will drop, but because the earnings are poised to rise.

0 Replies Reply Report this Post
 

Jorgedig (17.04)
Submitted December 1, 2007

I sold my Amgen just before the new, strict Medicare guidelines came through on the use of Aranesp to treat chemotherapy-induced anemia. <br /><br /> <br /><br />I work in a cancer clinic, and we are … More

1 Replies Reply Report this Post

News & Commentary Rss Feed

4 Reasons You Should Watch This Under-the-Radar Stock on Your Watchlist

Little known NPS Pharmaceuticals has fallen hard of late, along with other biotechs. Yet there are four compelling reasons why you should keep tabs on this stock.

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.

Here's what you need to know about Amgen (AMGN) and Biogen's (BIIB) upcoming first quarter earnings report.

Noteworthy ETF Inflows: XLV, JNJ, AMGN, BMY

Are Biotechs Bad Medicine for the S&P 500?

Are biotechs to blame for the recent downturn in the S&P 500?

Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend?

Last week saw a widespread downturn among biotech stocks. Regeneron Pharmaceuticals, however, was able to move modestly higher. Why?

Amgen's Conundrum

What will Amgen do with T-VEC and will it be able to compete with Bristol-Myers Squibb's Yervoy, which is already on the market, and Merck's (NYSE: MRK) experimental anti-PD-1 antibody MK-3475.

The Cost to Treat Cholesterol Plummets, But Will It Last?

Thanks to growing use of generics, spending on cholesterol treatments is falling. However, that may change once PCSK9 drugs from Amgen (AMGN), Regeneron (REGN), and Pfizer (PFE) reach the market.

Are Celgene and Amgen Undervalued By the Market?

Celgene (CELG) and Amgen (AMGN) shares have fallen as investors have shifted away from biotech, but that may not mean they're cheap yet.

Amgen Breaks Below 200-Day Moving Average - Notable for AMGN

Who Bucked the Short Interest Trend in Biotech Stocks?

See More AMGN News...

Sector

Healthcare

Industry

Drugs

Amgen, Inc. (AMGN) Description

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Website: http://www.amgen.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks